Treatment effect hazard ratios (95% CIs) and Kaplan-Meier estimates of eight-year times to event for four endpoints in the HR-positive/HER2-negative subgroups of SOFT and TEXT, for the two primary analysis populations (ie, SOFT overall and combined TEXT plus SOFT) and by cohort (defined by trial and chemotherapy use).[1] The median follow-up was eight and nine years in SOFT and TEXT, respectively.
Reference:
- Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122.
From: Regan MM, Fleming GF, Walley B, et al. Adjuvant systemic treatment of premenopausal women with hormone receptor–positive early breast cancer: Lights and shadows. J Clin Oncol 2019; 37(11):862-866. Reprinted with permission. Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
